CIBR vs XBI
First Trust NASDAQ Cybersecurity ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.58% for CIBR.
- • CIBR pays a higher dividend yield (0.39%).
Side-by-side metrics
| Metric | CIBR | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.58% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.39% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $17.53B | $10.92B |
YTD return | 32.86% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.03 | 1.01 |
P/E ratio | 27.94 | — |
Last price | $97.59 | $156.41 |
Inception | — | — |
Issuer | First Trust | State Street |
CIBR top holdings
| CRWD | CrowdStrike Holdings Inc Class A | 8.61% |
| PANW | Palo Alto Networks Inc | 7.58% |
| CSCO | Cisco Systems Inc | 7.48% |
| AVGO | Broadcom Inc | 7.09% |
| FTNT | Fortinet Inc | 6.20% |
| OKTA | Okta Inc Class A | 4.60% |
| ZS | Zscaler Inc | 4.38% |
| NET | Cloudflare Inc | 3.87% |
| RBRK | Rubrik Inc Class A Shares | 3.07% |
| FFIV | F5 Inc | 2.89% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About CIBR
CIBR (First Trust NASDAQ Cybersecurity ETF) is Cybersecurity companies providing network security. Managed by First Trust, the fund carries $17.5B in assets under management, an expense ratio of 0.58%, a dividend yield of 0.39%. Its largest holding is CrowdStrike Holdings Inc Class A (CRWD), which represents 8.6% of the portfolio. Technology is the fund's largest sector exposure at 95.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.